Inhaled Nitric Oxide After Out-of-Hospital Cardiac Arrest
Terminated · Phase 2 · NCT03079102
Conditions: Heart Arrest, Out-Of-Hospital
At a glance
- Research payments reported, 2025
- $129,558
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 57
About the trial
- Sponsor
- Cameron Dezfulian (with Mallinckrodt)
- Tested
- Nitric Oxide (drug), Nitrogen (drug)
- Dates
- Started 2017-08-26; completion 2020-06-02
- Results posted
- Yes
Phase II double blind (participants and investigator) placebo controlled randomized (1:1) clinical trial of inhaled nitric oxide (iNO) 20 ppm administered over 12h beginning as soon as possible but within 4 h of return of spontaneous circulation (ROSC) from out-of-hospital cardiac arrest (OHCA). Planned enrollment is 180 subjects over 48 months at University of Pittsburgh Medical Center (UPMC) Hospitals with randomization stratified in blocks of 8. Recruitment will be performed under exception from informed consent (EFIC) to facilitate early enrollment and treatment. The study will have a pre-specified safety analysis at the mid-point (after 1 year or 60 patients whichever occurs first). …
From ClinicalTrials.gov, last updated 2022-04-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Mallinckrodt Hospital Products Inc. reported $129,558 in research payments for this study in 2025 (1 payments).
Products named: Inomax
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Pittsburgh $129,558
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.